We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Failing Hearts Switch Fuels to Continue Generating Energy

By LabMedica International staff writers
Posted on 24 Feb 2016
A new study provides fresh biochemical insight into heart failure and may eventually lead to new diagnostic and pathology tests as well as therapeutic targets to prevent or slow progression of the disease. More...
The findings suggest a new approach to help treat early stages.

The research was led by Daniel Kelly, MD, scientific director of the Lake Nona campus of Sanford Burnham Prebys Medical Discovery Institute (SPB; La Jolla, CA & Lake Nona, FA, USA) as a collaborative study by scientists from SPB, Duke University, University of Illinois, and University of Cologne.

“Our research shows that as the heart fails, it loses its ability to burn fatty acids—the building blocks of fat—and instead starts using ketone bodies as an alternative fuel. It’s almost like the heart is starving because it doesn’t have the enzymatic machinery to burn fat anymore,” said Dr. Kelly.

To better understand what metabolic changes occur in place of fatty acid-burning, the team studied well established mouse models of the early and late stages of heart failure. They analyzed heart muscle cells to identify enzymes involved in metabolizing fuel that may ultimately become targets for therapies. They found that levels of BDH1, an enzyme involved in ketone metabolism, were 2x as high in mice with both early stage and complete heart failure compared to normal animals.

“It was surprising that BDH1 was increased in the failing heart, because this is an enzyme that is involved in burning ketones,” said Dr. Kelly, “We find it more in brain and liver, but one wouldn’t expect it to be very active in the heart.”

The new results suggest that a heart in the midst of failure has the ability to reprogram itself to take in more ketones and use them in a lower oxygen consumption fuel metabolism than fatty acid metabolism. Future studies on whether this is a productive or a faulty adaptive fuel shift could lead to new therapeutic avenues. Improved treatments would also be good news as the prevalence of heart failure is expected to increase in the coming years.

The study was published January 27, 2016, in the journal Circulation.

Related Links:

Sanford Burnham Prebys Medical Discovery Institute



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.